This study will evaluate the effects of daily paraxanthine supplementation on electronic gaming performance, cognitive function, sleep quality, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group study and assigned to receive either paraxanthine or placebo daily for 6 weeks.

Outcome measures will be assessed at baseline, Week 3, and Week 6 and will include electronic gaming performance, cognitive function, visual analog scale ratings, sleep quality questionnaires, hemodynamic responses, and heart rate variability. The study is designed to determine whether paraxanthine supplementation improves performance and selected physiological and psychological outcomes during prolonged electronic gaming sessions.

Electronic gaming has grown substantially in popularity, with increasing interest in strategies that may improve performance, cognitive function, sleep quality, and stress management. Despite this growth, there is limited controlled research evaluating nutritional interventions that may influence gaming-specific performance and associated physiological responses.

Paraxanthine is a primary metabolite of caffeine and has been shown to exhibit physiological effects related to alertness, cognitive performance, and central nervous system activity. However, limited research has evaluated the direct effects of paraxanthine supplementation on performance outcomes in electronic gaming environments.

This study is a randomized, double-blind, placebo-controlled, parallel-group trial designed to examine the effects of paraxanthine supplementation on electronic gaming performance and associated cognitive, psychological, and physiological responses. Participants will be assigned to receive paraxanthine or placebo daily for 6 weeks. All participants and study personnel involved in testing and outcome assessment will remain blinded to group assignment throughout the study.

Following screening and informed consent, eligible participants will complete a familiarization session to practice cognitive testing procedures and become oriented to the gaming environment. Participants will complete testing visits at baseline (Week 0), Week 3, and Week 6. Prior to each visit, participants will replicate their dietary intake for 24 hours, maintain their normal caffeine intake pattern, avoid non-habitual stimulants for 48 hours, limit caffeine intake within 3 hours of testing, and complete a 3-hour fast.

At each visit, participants will undergo assessment of body mass, resting heart rate, and blood pressure, followed by completion of sleep questionnaires, cognitive testing, and visual analog scales. After ingestion of the assigned supplement, participants will complete heart rate variability assessment and then perform two standardized 60-minute gaming sessions. Cognitive outcomes, hemodynamic responses, and subjective measures will be reassessed after each gaming period. Heart rate variability will also be assessed following completion of the gaming session.

Electronic gaming performance will be assessed using standardized gameplay metrics collected during each session. Cognitive function will be evaluated using validated neurocognitive tests, and sleep quality will be assessed using standardized questionnaires. Autonomic function will be evaluated using heart rate variability measures.

The primary objective of this study is to determine whether paraxanthine supplementation improves electronic gaming performance, cognitive function, and subjective measures of fatigue, concentration, and focus compared with placebo. Secondary objectives include evaluating the effects of supplementation on sleep quality, heart rate variability, and hemodynamic responses.

Inclusion Criteria:

• 18 - 40 years of age
• Self-reported to be beginners to gaming or have no experience at all
• Body Mass Index between 18.5 - 29.9 kg/m2

Exclusion Criteria:

• Outside of age range
• Is considered a gamer
• Body mass index is outside of posted inclusion range
• Noncompliance with protocol
• Women who are currently pregnant or are actively planning to become pregnant

This study will employ a double-blind design in which participants, investigators, and study personnel involved in data collection and outcome assessment are blinded to group assignment. Study supplements will be provided in identical capsules and packaging to ensure blinding. Group assignments will be coded and maintained by an independent party not involved in study procedures or data analysis and will remain concealed until completion of data collection and primary analyses.